UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020300
Receipt number R000023445
Scientific Title Effect of Carnitine Treatment on HCV in liver cirrhosis patients with hepatitis C virus infection
Date of disclosure of the study information 2015/12/21
Last modified on 2019/02/14 10:00:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Carnitine Treatment on HCV in liver cirrhosis patients with hepatitis C virus infection

Acronym

Effect of Carnitine on HCV

Scientific Title

Effect of Carnitine Treatment on HCV in liver cirrhosis patients with hepatitis C virus infection

Scientific Title:Acronym

Effect of Carnitine on HCV

Region

Japan


Condition

Condition

Liver cirrhosis Patients with HCV infection

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the virological and biochemical effect of carnitine administration in patients with a chronic HCV infection

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of serum HCV titer

Key secondary outcomes

) Change of oxidant stress maker and blood biochemistry
2) Presence or absence of a reversal of liver fibrosis
3) Presence or absence of an improvement in AFP levels
4) Effects of glucose/lipid-related factors on treatment response
5) Incidence of AEs


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria


[1] Patients who are 20 years of age or older at the time of informed consent
[2] Patients who have been fully informed and have provided written informed consent to participate in this study prior to study initiation
[3] Patients with a chronic HCV infection who do not meet any of the following exclusion criteria

Key exclusion criteria

1) Patients with poorly controlled cardiac disease (e.g., myocardial infarction, cardiac failure, arrhythmia)
2) Patients with severe hepatic impairment
3) Patients with a concurrent malignancy, including hepatocellular carcinoma, at the start of treatment
4) Patients who are unsuitable, in the opinion of the principal investigator, for this study due to any other reason

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Goki Suda

Organization

Hokkaido University

Division name

Department of Gastroenterology and Hepatology, Graduate School of Medicine,

Zip code


Address

Kita 14-jo Nishi 5-jo, Kita-ku, Sapporo city, Hokkaid

TEL

+81-11-716-1161

Email

gsudgast@pop.med.hokudai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Goki Suda

Organization

Hokkaido University

Division name

Department of Gastroenterology and Hepatology, Graduate School of Medicine,

Zip code


Address

Kita 14-jo Nishi 5-jo, Kita-ku, Sapporo city, Hokkaid

TEL

+81-11-716-1161

Homepage URL


Email

gsudgast@pop.med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University

Institute

Department

Personal name



Funding Source

Organization

Hokkaido University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学病院(北海道)


Other administrative information

Date of disclosure of the study information

2015 Year 12 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2014 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is cohort study
Way for subscription
Patients who visit our hospital between May 2014 and march 2018, and meet inclusion criteria are enrolled.


Management information

Registered date

2015 Year 12 Month 21 Day

Last modified on

2019 Year 02 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023445


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name